ATS 2019 Virtual Final Program

112 Minimal Clinically Important Distance Measured by Six-Minute Walking Distance in Patients with IPAH/ K. Bunclark, Y.-D. Chiu, S.S. Villar, M. Newnham, J. Cannon, M. Toshner, K. Sheares, D. Taboada, J. Pepke-Zaba, Cambridge, United Kingdom, p.A2513 113 Subtypes and Outcomes of Sarcoidosis-Associated Pulmonary Hypertension/ J. Wang, S. Brusca, M. Sharp, T.M. Kolb, P.M. Hassoun, R.L. Damico, S.C. Mathai, Baltimore, MD, p.A2514 114 Assessing Predictive Quality of Diastolic Pulmonary Gradient in Precapillary and Postcapillary Pulmonary Hypertension/ H. Deshwal, E. Covert, M. Li, X. Wang, N.F. Chaisson, A. Goyanes, K.B. Highland, A.R. Tonelli, R.A. Dweik, G.A. Heresi, Cleveland, OH, p.A2515 115 Increasing Age Is Associated with Worsening Physical Function Despite More Favorable Cardiopulmonary Hemodynamics: A Pulmonary Hypertension Association Registry (PHAR) Report/ J.T. DesJardin, N.A. Kolaitis, N. Kime, R. Kronmal, S. Bartolome, D.B. Badesch, R.L. Benza, E.B. Rosenzweig, C.D. Burger, T.M. Bull, M.M. Chakinala, J.M. Elwing, J.P. Feldman, J. Fineman, D. Grinnan, E. Horn, M.R. Lammi, S.C. Mathai, J.W. McConnell, K.W. Presberg, J. Robinson, J.S. Sager, O.A. Shlobin, M. Simon, T. Thenappan, R.T. Zamanian, T. DeMarco, San Francisco, CA, p.A2516 116 PVDOMICS: Early Clinical Findings Across the Spectrum of Pulmonary Hypertension/ A. Hemnes, Nashville, TN, p.A2517 117 Prognostic Impact of Exercise Pulmonary Hypertension in Patients with Unexplained Dyspnea/ R. Oliveira, M. Faria Urbina, A.B. Waxman, D.M. Systrom, Sao Paulo, Brazil, p.A2518 118 Neuromodulation as a New Strategy in Management of Pulmonary Hypertension/ M. Ahmed, K. Ochani, C. Li, L. Ke, E.J. Miller, Manhasset, NY, p.A2519 119 Effect of Inhaled Albuterol on Pulmonary Vascular Resistance in Patients with Group 1 Pulmonary Arterial Hypertension on Oral Pulmonary Vasodilator Therapy: A Proof of Concept Study/ D.J. De La Zerda, I.Y. Gutierrez Puentes, B.E. Hurwitz, E.S. Mendes, M. Parker, J. Arana, A. Wanner, Miami, FL, p.A2520 120 Hepatoma-Derived Growth Factor (HDGF) Is a Predictor of Disease Severity and Survival in Pulmonary Arterial Hypertension and Highly Associated with Portal Pulmonary Hypertension/ J. Yang, M. Nies, M. Griffiths, R. Damico, D. Vaidya, S. Brandal, M. Pauciulo, E. Austin, D. Ivy, W. Nichols, A. Everett, Baltimore, MD, p.A2521 121 Early Versus Late Initiation of Treatment with Prostacyclin-Class Therapy in Patients with Pulmonary Arterial Hypertension (PAH)/ R.H. Anguiano, D. Stafkey-Mailey, V. Saundankar, B. Dean, P. Classi, K. Gordon, A. Nails, A. Nelsen, Chicago, IL, p.A2522 122 Right Ventricular Dysfunction by Speckle-Tracking Echocardiography as a Predictor of Outcomes in Acute Respiratory Failure Requiring Mechanical Ventilation/ J. Simmons, P. Haines, J.M. Aliotta, J. Extein, G. Baird, C.E. Ventetuolo, Providence, RI, p.A2523 123 Upfront Combination Versus Monotherapy in Pulmonary Arterial Hypertension (PAH): Can Advanced Risk Stratification Tell Us the Real Benefit?/ J.V. Scott, L.C. Lohmueller, C.G. Garnett, M.K. Kanwar, R.L. Benza, Pittsburgh, PA, p.A7346 CLINICAL • TRANSLATIONAL RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION A106 NTM: BENCH TO BEDSIDE 2:15 p.m. - 4:15 p.m. KBHCCD Ballroom A Four (Level 2) Abstract Summaries 2:15-2:45 Viewing/Discussion 2:45-4:15 Chairing: T.K. Marras, MD, Toronto, Canada M. Holt, MBBS, BSc, Denver, CO J. Philley, MD, Tyler, TX 301 Comparison of Characteristics of Fibrocavitary and Bronchiectasis Phenotypes of Pulmonary Mycobacterium Avium/ J. Lio, Y. Lee, R. Obata, New York, NY, p.A2524 302 Nontuberculous Mycobacterial Pulmonary Disease in Patients with Interstitial Pneumonia/ Y. Goto, Y. Yamano, T. Yokoyama, T. Matsuda, K. Kataoka, T. Kimura, Y. Kondoh, Seto, Japan, p.A2525 303 Comparison of Clinical Characteristics in Patients with Single and Multiple Species Nontuberculous Mycobacterial Pulmonary Disease/ E. Lee, Y. Park, S.H. Yong, M.S. Park, Y.S. Kim, Y. Kang, Seoul, Korea, Republic of, p.A2526 304 Pulmonary Emphysema Is Associated with Fibrocavitary Mycobacterium Avium Complex Lung Disease/ A. Yamamoto, K. Tamura, T. Masuda, S. Takahashi, Y. Tanaka, Y. Kishimoto, O. Kyohei, Y. Endo, M. Saigusa, T. Akamatsu, S. Morita, K. Asada, T. Shirai, Shizuoka, Japan, p.A2527 305 Lady Windermere’s Dudemere? Pulmonary NTM in Men/ J.H. Ku, G.P. Ranches, S.A.R. Siegel, K.L. Winthrop, Portland, OR, p.A2528 306 Long-Term Natural Course of Pulmonary Mycobacterium Avium Complex Disease Evaluated with Serial Computed Tomography/ A. Shiorshita, Y. Tanaka, K. Nakashima, Kamogawa City, Japan, p.A2529 307 Factors Associated with Frailty in Patients with Mycobacterium Avium Complex Lung Disease/ K. Fujita, Y. Ito, N. Uchida, Y. Yamamoto, O. Kanai, M. Okamura, K. Nakatani, T. Mio, Kyoto, Japan, p.A2530 308 A Comparison of the Clinical and Radiological Findings in Patients of Pulmonary MAC Disease Based on Smoking History and Gender/ N. Kodaka, Tokyo, Japan, p.A2531 309 Comparison of the Surgical Lung Histopathologic Features of Patients with Pulmonary Disease Due to Mycobacterium Avium Complex Versus Mycobacterium Abscessus Complex/ E.D. Chan, K.J. Potts, C. Cool, M. Althoff, S.D. Groshong, S. Choi, Denver, CO, p.A2532 ATS 2019 • Dallas, TX SUNDAY • MAY 19 113 SUNDAY AFTERNOON